GlassScriptPhysician profile
Keren Lerner
NPI 1295998052
$2,749.78
in general payments reported to CMS, 2019-2025
26 companies · $875 in 2025
The $875 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $89.05 · 2021: $331 · 2022: $373 · 2023: $447 · 2024: $254 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.94 | 2019-2025 | |
| Astellas Pharma US INC | $291.98 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $263.74 | 2021-2025 | |
| Sage Therapeutics, LLC | $232.50 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $208.86 | 2019-2025 | |
| Exeltis, USA INC. | $151.31 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $123.47 | 2022-2023 | Twirla |
| Allergan, INC. | $115.84 | 2019 | |
| Therapeuticsmd, INC. | $109.25 | 2019-2022 | |
| Evofem Biosciences, INC. | $91.37 | 2021-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $82.30 | 2020-2025 | Paragard T 380a |
| Novo Nordisk INC | $55.60 | 2023-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $49.01 | 2024-2025 | Myfembree |
| Millicent US INC | $48.04 | 2025 | Intrarosa, Femlyv |
| Pfizer INC. | $44.43 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $35.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $31.97 | 2022-2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $26.83 | 2019-2020 | |
| Hologic Sales and Service, LLC | $25.14 | 2024 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $22.17 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.77 | 2025 | Qelbree |
| Shield Therapeutics INC | $19.66 | 2023 | Accrufer |
| Ibsa Pharma INC. | $19.12 | 2025 | Tirosint, Licart, Flector |
| Amag Pharmaceuticals, INC. | $18.70 | 2020 | |
| Medicem INC. | $14.32 | 2022 | |
| Ascend Therapeutics US, LLC | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keren Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.